ITI-722 manufacturers
- ITI-722
-
- $0.00 / 1kg
-
2025-05-16
- CAS:313368-91-1
- Min. Order: 1kg
- Purity: 98
- Supply Ability: 1000
- Lumateperone
-
- $33.00 / 10mg
-
2025-04-29
- CAS:313368-91-1
- Min. Order:
- Purity: 99.77%
- Supply Ability: 10g
- Lumateperone
-
- $0.00 / 10mg
-
2025-03-27
- CAS:313368-91-1
- Min. Order: 10mg
- Purity: 0.98
- Supply Ability: 5g
|
| Product Name: | ITI-722 | | Synonyms: | ITI-722;ITI-722 lumateperone;1-(4-fluorophenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3‘,4‘:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)butan-1-one;313368-91-1Lumateperone(ITI-007);1-Butanone, 1-(4-fluorophenyl)-4-[(6bR,10aS)-2,3,6b,9,10,10a-hexahydro-3-methyl-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl]-;1-(4-fluorophenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,7,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(9H)-yl)butan-1-one;1-(4-Fluorophenyl)-4-[(6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl]-1-butanone;Lumateperone | | CAS: | 313368-91-1 | | MF: | C24H28FN3O | | MW: | 393.5 | | EINECS: | | | Product Categories: | API | | Mol File: | 313368-91-1.mol |  |
| | ITI-722 Chemical Properties |
| Boiling point | 556.4±50.0 °C(Predicted) | | density | 1.26±0.1 g/cm3(Predicted) | | pka | 9.10±0.20(Predicted) | | form | Oil | | color | Colorless to light yellow |
| | ITI-722 Usage And Synthesis |
| Physical Form | white solid | | Description | Lumateperone is a novel antipsychotic agent with a unique mechanism of
action with high 5-hydroxytryptamine 2A(5-HT2A) blocking activity. A
Phase 2 study in treatment of insomnia revealed strong evidence of
efficacy, with no impairment of next-day cognition.
| | Uses | Lumateperone was a drug developed for the treatment of schizophrenia. May have applications in bipolar depression. | | in vivo | Lumateperone (i.p., 1-10 mg/kg) promotes NMDA and AMPA-induced currents in a dopamine D1 receptor-dependent manner and increases the release of dopamine and glutamate in rat mPFC slices[2].
| Animal Model: | Adult male Sprague-Dawley rats[2] | | Dosage: | 1-10 mg/kg | | Administration: | Intraperitoneal injection | | Result: | Inhibited avoidance response at concentrations of 1, 3 and 10 mg/kg after 20 minutes.
Promoted NMDA and AMPA-sensitive currents, also significantly increased dopamine and glutamate release at 10 mg/kg in mPFC cone cells of rat.
|
| | IC 50 | D1 Receptor; D2 Receptor | | storage | Store at 0-8℃ |
| | ITI-722 Preparation Products And Raw materials |
| Raw materials | 4'-fluoro-4-iodobutyrophenone-->1H-Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline, 2,3,6b,7,8,9,10,10a-octahydro-3-methyl--->(6bR,10aS)-3-Methyl-2,3,6b,7,8,9,10,10a-octahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline-->4-FLUOROPHENYLMAGNESIUM BROMIDE-->4-Chloro-4'-fluorobutyrophenone |
|